ART Advanced Research Technologies to be Present at the Annual Meeting of the American Society for Cell Biology in Washington, D
November 29 2007 - 2:35PM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, will be exhibiting at the
American Society for Cell Biology (ASCB) 47th Annual Meeting, Dec.
1-5, 2007, Washington, DC. ART will showcase its preclinical
product offering, including the Optix� MX2 optical imaging device
and the Fenestra� line of contrast agents for micro-CT imaging at
its booth (#853) located in the Exhibit Hall of the Washington
Convention Center. ART's Optix MX2 platform enhances molecular
imaging research for the life scientist. By applying ART's
proprietary time domain technology to biology a scientist can gain
incremental sensitivity, specificity, and depth data from
fluorescent labelled compounds. This technique can apply to
specific receptors, antibodies, epitopes and drugs for in vivo
preclinical research.
As the largest and most important international meeting in the
field of cell biology, the ASCB Annual Meeting brings together
scientists and students in academia, industry, government, and
higher education. Over 100 scientific sessions and 3,500 poster
presentations cover a variety of scientific areas within the
discipline. With opportunities to learn about the latest research
and network with peers, the ASCB Annual Meeting appeals to the
diverse interests of the international cell biology community.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART in North America and Europe
and is used by industry and academic leaders worldwide. The
SoftScan� optical breast imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
the SoftScan optical medical imaging device via a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. Finally, the Fenestra� line of molecular imaging contrast
products provide image enhancement for a wide range of preclinical
Micro CT applications allowing scientists to see greater detail in
their imaging studies, with potential extension into other major
imaging modalities. The distribution of the Fenestra line of
imaging contrast agents is made through GE Healthcare Bio-Science
KK in Japan and is sold directly by the Company in the rest of the
world. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at www.art.ca
.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques
B�dard Chief Financial Officer 514-832-0777 jbedard@art.ca
www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024